AstraZeneca’s dapagliflozin recommended by NICE
Treatment concerns up to 150,000 patients in England with chronic heart failure
Read More
Tag: dapagliflozin
AZ’ Farxiga hits all goals in chronic kidney disease trial
The drug significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type II diabetes
Read More
AZ’ Farxiga fast-tracked for heart failure following MI
The move is based on the first indication-seeking registry-based randomised controlled trial
Read More
US OK’s AZ’ Farxiga for heart failure with reduced ejection fraction
Farxiga is the first sodium glucose co-transporter 2 inhibitor cleared by the FDA to treat heart failure with reduced ejection fraction
Read More
AZ, Saint Luke’s begin testing Farxiga for COVID-19
DARE-19 will determine whether Farxiga can hold back disease progression and reduce the risk of clinical complications and death
Read More
Positive results continue success for Forxiga
Forxiga has had a string of successes recently, as it was recommended by NICE and had its EU marketing authorisation updated earlier this month.
Read More
AZ’ Forxiga label updated in EU for type II diabetes
The decision comes from positive cardiovascular outcomes and renal data from the Phase III DECLARE-TIMI 58 trial.
Read More
AZ’ Farxiga hit with complete response letter
AstraZeneca has said that it will work closely with the FDA to discuss the next steps.
Read More
NICE recommends Skyrizi, Forxiga
The recommendations are for the indication of plaque psoriasis and type I diabetes, respectively.
Read More
EU approves AZ’ Forxiga for type I diabetes
The drug is the first oral medicine approved in Europe as an adjunct to insulin for adults with type I diabetes.
Read More
AZ’ Farxiga shows CV benefit in diabetes patients
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
Read More
Farxiga cuts hospitalisation for heart failure or CV death, study shows
AstraZeneca has unveiled new data showing a statistically-significant reduction in hospitalisation for heart failure or cardiovascular (CV) death in a broad population of patients with type II diabetes taking Farxiga.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
